Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Dose De-escalation Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression

Trial Profile

A Phase 1b Dose De-escalation Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Dinaciclib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 31 Aug 2018 Biomarkers information updated
    • 16 Apr 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top